key: cord-0832391-i29e3fge
authors: Huang, Kuan-Ying A.; Tan, Tiong Kit; Chen, Ting-Hua; Huang, Chung-Guei; Harvey, Ruth; Hussain, Saira; Chen, Cheng-Pin; Harding, Adam; Gilbert-Jaramillo, Javier; Liu, Xu; Knight, Michael; Schimanski, Lisa; Shih, Shin-Ru; Lin, Yi-Chun; Cheng, Chien-Yu; Cheng, Shu-Hsing; Huang, Yhu-Chering; Lin, Tzou-Yien; Jan, Jia-Tsrong; Ma, Che; James, William; Daniels, Rodney S.; McCauley, John W.; Rijal, Pramila; Townsend, Alain R.
title: Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans
date: 2020-08-28
journal: bioRxiv
DOI: 10.1101/2020.08.28.267526
sha: 5c70fed2fcb55a4d891af3c5b752b46aa7204b79
doc_id: 832391
cord_uid: i29e3fge

Plasmablast responses and derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients. An average of 13.7% and 13.0% of plasmablast-derived IgG MAbs were reactive with virus spike glycoprotein or nucleocapsid, respectively. Of thirty-two antibodies specific for the spike glycoprotein, ten recognised the receptor-binding domain (RBD), thirteen were specific for non-RBD epitopes on the S1 subunit, and nine recognised the S2 subunit. A subset of anti-spike antibodies (10 of 32) cross-reacted with other betacoronaviruses tested, five targeted the non-RBD S1, and five targeted the S2 subunit. Of the plasmablast-derived MAbs reacting with nucleocapsid, over half of them (19 of 35) cross-reacted with other betacoronaviruses tested. The cross-reactive plasmablast-derived antibodies harboured extensive somatic mutations, indicative of an expansion of memory B cells upon SARS-CoV-2 infection. We identified 14 of 32 anti-spike MAbs that neutralised SARS-CoV-2 in independent assays at ≤ 133 nM (20 μg/ml) (five of 10 anti-RBD, three of 13 anti-non-RBD S1 subunit, six of nine anti-S2 subunit). Six of 10 anti-RBD MAbs showed evidence of blockade of ACE2 binding to RBD, and five of six of these were neutralising. Non-competing pairs of neutralising antibodies were identified, which offer potential templates for the development of prophylactic and therapeutic agents against SARS-CoV-2.

In late 2019, a novel coronavirus emerged and was identified as the cause of a cluster 54 of respiratory infection cases in Wuhan, China. It spread quickly around the world. In 55

March of 2020 a pandemic was declared by the World Health Organization , the virus 56 was formally named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-57

CoV-2) and the resulting disease was named COVID-19. As of 12 August 2020, there 58 have been over 20 million confirmed cases of SARS-CoV-2 infection with 737,417 59 deaths (World Health Organization, https://covid19.who.int/). 60

There is no fully effective drug or licenced vaccine for COVID-19. Antibodies 61 neutralise SARS-CoV-2 in vitro, offering hope that a vaccine may induce a protective 62 response, and antibodies may be an effective treatment for COVID-19 in clinical 63 practice. Convalescent plasma is being tested in ongoing clinical trials as a therapy for 64 glycoproteins of other betacoronaviruses, including SARS, MERS or human common 135 cold coronavirus OC43 in ELISA (Table 1) three of these also cross-reacted on MERS (Table 1 ). All five cross-reactive anti-S2 145 antibodies had high rates of somatic mutation (25±5), indicating a memory 146 phenotype, and three of the five were neutralising to a moderate level (half maximal 147 effective concentration, EC 50 , 36-133.33 nM, Table 1 ). 148

The CDR3 length varied among anti-spike glycoprotein antibodies (Supplementary  149   Table 2 ). No significant differences were found between anti-S2 and anti-S1 or anti-150 RBD subsets. Among anti-S2 MAbs, a significantly longer heavy chain CDR3 length 151 was found in the cross-reactive group compared to the specific group (Cross-reactive 152 20±2 versus Specific 12±4, p= 0.02; Figure 2c ), indicating that a long CDR3 may 153 play a role in antigen binding, which is also found in several broadly reactive human 9

The binding sites of 10 anti-RBD MAbs were further characterised in detail. Using 157 MDCK-SIAT1 cells transduced to express the RBD and flow cytometry, binding 158 activities of the anti-RBD MAbs were shown to vary with 50% binding concentration 159 from 0.10 to 1.83 µg/ml (see methods; Supplementary Figure 2 ). The MAbs with 160 strong anti-RBD binding have a relatively long heavy chain CDR3 length (50% 161 binding concentration <0.5 µg/ml versus >0.5 µg/ml, p=0.03; Supplementary Figure  162 3). 163

The ten anti-RBD IgG MAbs were divided into cross-inhibiting groups as described 165

for human MAbs to Ebola (11) by assessing competition of unlabelled antibodies at Therefore, in competition experiments we used the RBD-VLP molecule bound to the 177 plate to display RBD to antibodies or ACE2-Fc. 178

The ten antibodies formed four cross-inhibiting clusters (Table 2) were detected in clusters 1, 2 and 3, with the strongest antibodies FI 3A and FD 11A 183 being in clusters 2 and 3 (Tables 1 and 2) . 184

We compared two assays designed to detect antibody-blocking of the ACE2-RBD 186 interaction (Supplementary Figure 5 , Table 1 ), including an assay that we reported 187 previously (13, 16). In the first assay unlabelled MAbs in at least 10-fold excess were 188 mixed with biotin labelled ACE2-Fc and binding to the RBD, displayed on RBD-VLP 189 bound to an ELISA plate, was detected with Streptavidin-HRP (Supplementary Figure  190 5a). The definition of the antibody clusters in Table 2 was based on this assay. 191

We noted that when unlabelled ACE2-Fc was used to compete with labelled MAbs a 192 slightly different pattern was detected: for example, the unlabelled nanobody Fc in excess strongly inhibited the binding of labelled ACE2-Fc to RBD, but not vice-194 versa. The structure of VHH72-Fc bound to RBD is known (12) and its footprint on 195 the RBD does not overlap that of ACE2, so inhibition is thought to occur by steric 196 hindrance. The second example is the pair FD 5D and FD 11A in cluster 3. These 197 antibodies showed no inhibition of labelled ACE2-Fc, but the biotinylated versions 198 were strongly competed by unlabelled ACE2-Fc (Table 2) . 199

In the second assay, we employed MDCK-SIAT1 cells overexpressing full-length 200 human ACE2 as a transmembrane protein. Unlabelled antibodies or ACE2-Fc were 201 mixed in excess with biotinylated RBD, and binding of RBD was detected with 202 Streptavidin-HRP in ELISA (Supplementary Figure 5b) . The results of this assay 203 mostly mirrored those of the first assay and confirmed that in this orientation cluster 3 204 antibodies FD 5D and FD 11A competed in excess with soluble RBD for binding to 205 ACE2 (Supplementary Figure 5 ). In addition, antibodies in cluster 1 showed partial 206 (CR3022) or near complete (EY 6A) competition. These two antibodies are known to 207 bind to the same region of RBD away from the ACE2 binding site, but they influence 208 the binding kinetics of RBD to ACE2, presumably through steric effects (16). 209

The optimum method for detecting neutralisation of SARS-CoV-2 has not been 211 were identified: three of 13 to S1 (non-RBD), six of nine to S2, five of 10 to RBD. 223

The EC 50 concentrations, as a measure of potency, ranged from 0.05 nM to ~133.33 224 nM (8 ng/ml -~20 µg/ml). Corroboration for a selection of these antibodies was then 225 sought. 226

Neutralisation was corroborated by a microneutralisation test at Oxford (see 227 methods), that measured a reduction in fluorescent focus-forming units, summarised 12 in Table 1 Figure 7) . 236

Five neutralising MAbs target the RBD and all of these partially or completely 238 blocked the interaction between RBD and ACE2 in one or the other type of assay 239 (Tables 1 and 2 

Thirteen MAbs were defined that bound the S1 region and three, close to germline in 263 sequence, were neutralising. FJ 1C showed strong neutralisation (EC 50 55.5 nM), 264 whilst FD 11E (EC 50 70 nM) and FD 1E (EC 50 110 nM) were moderately neutralising 265 (Table 1) . We investigated the specificity of these antibodies using flow cytometry 266 with MDCK-SIAT1 cells expressing the N-terminal domain (NTD) of spike 267 glycoprotein linked to the transmembrane and cytoplasmic region of influenza 268 haemagglutinin (see methods). FJ 1C (neutralising) and FD 7C bound strongly to this 269 NTD construct defining them as NTD specific (Table 1, Supplementary Figure 8) . 270

In Table 1 The presence of pre-existing immune memory to betacoronavirus that cross-react with 332 SARS-CoV-2 is supported by the accumulation of somatic mutations in the genes 333 encoding cross-reactive antibodies isolated from COVID-19 patients (Figures 2c and  334   2d, Supplementary Tables 2 and 3 ). This situation is reminiscent of re-exposure to 335 immunogenic epitopes shared by closely related viruses leading to induction of 336 broadly cross-reactive antibodies in patients infected with influenza, dengue or Zika 337 viruses (28-30). 338

Our results have significance for serologic tests employing the N and S2 antigens of 339 SARS-CoV-2. Serologic surveys, some of which are based on these antigens, with 340 sera from donors infected with SARS-COV-2 during the spring and summer months 341 have shown very high specificity (as judged by comparing convalescent sera from COVID-19  patients  versus  sera  collected  in  the  pre-COVID-19  343 period)(www.gov.uk/government/publications/covid-19-laboratory-evaluations-of-344 serological-assays). However, if many individuals have memory B cells to S2 and N 345 antigens of circulating betacoronaviruses that cross-react with SARS-CoV-2, 346 concurrent winter infections with these viruses might erode the specificity of 347 serologic tests for SARS-CoV-2 based on these two antigens. Cross-reactivity of 348 antibodies targeting the RBD is much lower, so using this antigen is more likely to 349

give a true indication of SARS-CoV-2 specificity. 350

The 32 MAbs that bound to the spike glycoprotein were systematically tested for 352 neutralisation in two laboratories (summarised in Table 1 ). Results established that 353 neutralising epitopes were present on the RBD, S1-NTD, S1-non NTD/RBD, and S2 354 regions of the spike glycoprotein. The range of neutralisation EC 50 titres against live 355 SARS-CoV-2 reported in the literature for human and murine monoclonal antibodies 356 span at least three orders of magnitude, from ng/ml to µg/ml (31, 32). Our results 357 reflect this range. The relationship between EC 50 titre in neutralisation assays and 358 therapeutic potential is not established, although antibodies to the RBD with EC 50 in 359 the nanogram range have shown therapeutic activity in small animal models (33-35). 360

The majority of the most strongly neutralising antibodies were close to germline in 361 sequence, showing that full affinity maturation is not required in order to achieve The RBDs of SARS and SARS-CoV-2 are known to contain neutralising epitopes (16, 366 31-42), and vaccines based on the RBD of SARS and SARS-CoV-2 induce strong 367 neutralising antibodies that are protective in animal models (43-45). There is a 368 tendency for the most potent neutralising antibodies to be those that block the binding 369 of the RBD to its receptor ACE2 (31-42, 46-48). Occasional antibodies that do not 370 occupy the ACE2 footprint and fail to block ACE2 binding, can be almost as powerful 371

(40), perhaps through triggering a conformational change in the spike glycoprotein 372 that renders it non-functional (4, 16). 373

We describe ten MAbs targeting the RBD that can be arranged into four cross-374 inhibiting clusters ( Table 2) 

plaque forming units (PFU) of SARS CoV-2 (hCoV-19/England/02/2020, 507 EPI_ISL_407073) and antibodies in a 2-fold dilution series (triplicates) for 3 hours at 508 room temperature. Inoculum was then removed, and cells were overlaid with plaque 509 assay overlay. Cells were incubated at 37°C, 5% CO 2 for 24 hours prior to fixation 510 with 4% paraformaldehyde at 4°C for 30 minutes. Fixed cells were then 511 permeabilised with 0.2% Triton-X-100 and stained with a horseradish peroxidase 512 conjugated-antibody against virus protein for 1 hour at room temperature. TMB 513 substrate was then added to visualise virus plaques as described previously for 514 influenza virus (52). Convalescent serum from COVID-19 patients was used as a 515 control. 516

In brief, this rapid, high-throughput assay determines the concentration of antibody 518 that produces a 50% reduction in infectious focus-forming units of authentic SARS- The second ACE2 blocking assay was performed as described previously (13, 16) . Table 1 . The antigenic specificity, cross-reactivity and function of 32 anti-SARS-CoV-2 spike antibodies derived from COVID-19 patients. B non-NTD S1 pos 1.20 0.14 0.20 0.11 0.11 0.12 -ve partial FD 7D

B non-NTD S1 -ve 1.44 0.12 0.14 0.11 0.11 0.12 -ve -ve FD 8B

B non-NTD S1 -ve 1.10 0.14 0.12 0.08 0.10 0. 

Deployment of convalescent plasma for the prevention and 641 treatment of COVID-19

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement 643 in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical

Use of convalescent plasma therapy in SARS patients in Hong Kong

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike

Breadth of concomitant immune responses prior to patient 650 recovery: a case report of non-severe COVID-19

Neutralizing antibodies in patients with severe acute respiratory 652 syndrome-associated coronavirus infection

Antibody responses to SARS-CoV-2 in patients with COVID-19

Structural Basis for Potent Neutralization of Betacoronaviruses by

Single-Domain Camelid Antibodies

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block 666 interaction with ACE2

Human monoclonal antibody combination against SARS 668 coronavirus: synergy and coverage of escape mutants

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Structural basis for the neutralization of SARS-CoV-2 by an antibody 672 from a convalescent patient

Nanoscaffold To Enhance Plug-and-Display Vaccination

A highly conserved cryptic epitope in the receptor binding domains of

Protective humoral immunity in SARS-CoV-2 infected pediatric 679 patients

Antibody responses to SARS-CoV-2 in patients of novel coronavirus 681 disease 2019

Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal

Convergent antibody responses to SARS-CoV-2 in convalescent 713 individuals

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High

Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Potent neutralizing antibodies against multiple epitopes on SARS

A noncompeting pair of human neutralizing antibodies block COVID-19 720 virus binding to its receptor ACE2

Potent neutralizing antibodies from COVID-19 patients define 722 multiple targets of vulnerability

Studies in humanized mice and convalescent humans yield a SARS

CoV-2 antibody cocktail

Isolation of potent SARS-CoV-2 neutralizing antibodies and 726 protection from disease in a small animal model

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS

CoV antibody

Receptor-binding domain as a target for 737 developing SARS vaccines

The SARS-CoV-2 receptor-binding domain elicits a potent 739 neutralizing response without antibody-dependent enhancement

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces 742 protective immunity

Structural basis of receptor recognition by SARS-CoV-2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to 746 the ACE2 receptor

Structural and Functional Basis of SARS-CoV-2 Entry by Using 748

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 750 mutational escape seen with individual antibodies

A neutralizing human antibody binds to the N-terminal domain of the

Spike protein of SARS-CoV-2

Structure-function analysis of neutralizing antibodies to H7N9 754 influenza from naturally infected humans

Optimisation of a micro-neutralisation assay and its application in 756 antigenic characterisation of influenza viruses

Isolation and rapid sharing of the 2019 novel coronavirus

Acaricide, fungicide and drug interactions in honey bees (Apis 762 mellifera)

S generated 787 cell lines, expressed proteins and antibodies, and performed experiments

M helped prepare materials, perform experiments and analyse data